STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Clinical trials for STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to stop spine tumors from crushing the spinal cord
Disease control OngoingThis study tests whether using heat (thermal ablation) followed by precise radiation (stereotactic radiosurgery) can better control cancer that has spread to the spine and is pressing on the spinal cord. About 60 adults with various solid tumors and moderate to severe spinal cord…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 17, 2026 00:28 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests the safety and best dose of two drugs, ceritinib and everolimus, given together to adults with advanced solid tumors or a specific type of lung cancer (ALK-positive NSCLC). The goal is to find the highest safe dose and see if the combination can shrin…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
Experimental combo aims to outsmart Drug-Resistant lung cancer
Disease control OngoingThis early-phase trial tests a new two-drug combination (sapanisertib and osimertinib) in 36 adults with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to standard treatment. The main goal is to find the safest dose and identify side effects. This is …
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New combo therapy shows promise for advanced lung and colon cancers
Disease control OngoingThis study tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with radiation therapy can shrink tumors in people with metastatic colorectal or non-small cell lung cancer. About 110 adults with advanced cancer that has spread will receive the drugs alone…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New combo therapy shows promise for tough lung cancer
Disease control OngoingThis study tested two drugs, erlotinib and cabozantinib, given alone or together in 125 people with advanced non-small cell lung cancer that had already been treated. The goal was to see if the combination worked better than either drug alone at slowing cancer growth. Participant…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or can't be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the drug combo can shrink tum…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
New combo therapy targets tough lung cancer mutation
Disease control OngoingThis study tested a combination of two drugs, trametinib and docetaxel, in 60 people with a specific genetic subtype of advanced lung cancer (KRAS mutation) that had worsened after prior treatments. The goal was to see if the combination could shrink tumors. The approach uses one…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC